Winthrop Arzneimittel GmbH - search results

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; indigo carmine; iron oxide black; titanium dioxide; pregelatinised maize starch - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ramipril winthrop ramipril 2.5mg tablet blister pack

sanofi-aventis australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; hypromellose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ramipril winthrop ramipril 1.25mg tablet blister pack

sanofi-aventis australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

triamcinolone-winthrop nasal spray

winthrop pharmaceuticals (pty) ltd - nasal spray - each actuation delivers triamcinolone acetonide 55,0 ug